State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Biochemistry, Peking Union Medical College, Beijing, 100005, China.
Sci China Life Sci. 2023 Oct;66(10):2370-2379. doi: 10.1007/s11427-022-2275-3. Epub 2023 Mar 17.
Hypertension has become a growing public health concern worldwide. In fact, hypertension is commonly associated with increased morbidity and mortality. Currently, oligonucleotide drugs have proven to be promising therapeutic agents for various diseases. In the present study, we aimed to demonstrate that a herbal small RNA (sRNA), XKC-sRNA-h3 (B55710460, F221. I000082.B11), exhibits potent antihypertensive effects by targeting angiotensin-converting enzyme (ACE) in mice. When compared with captopril, oral administration of the sphingosine (d18:1)-XKC-sRNA-h3 bencaosome more effectively prevented angiotensin II-induced hypertensive cardiac damage and alleviated kidney injury in mice. Such findings indicated that XKC-sRNA-h3 may be a novel orally available ACE inhibitor type oligonucleotide drug for hypertension.
高血压已成为全球日益严重的公共卫生问题。事实上，高血压通常与发病率和死亡率的增加有关。目前，寡核苷酸药物已被证明是治疗各种疾病的有前途的治疗剂。在本研究中，我们旨在证明一种植物小分子 RNA（sRNA），XKC-sRNA-h3（B55710460，F221. I000082.B11），通过在小鼠中靶向血管紧张素转换酶（ACE）发挥强大的降压作用。与卡托普利相比，口服鞘氨醇（d18：1）-XKC-sRNA-h3 脂质体更有效地预防了血管紧张素 II 诱导的高血压性心脏损伤，并减轻了小鼠的肾脏损伤。这些发现表明，XKC-sRNA-h3 可能是一种新型的可口服的 ACE 抑制剂型寡核苷酸药物，可用于治疗高血压。
